- Home
- WMPN vs ANL Comparison
WMPN vs ANL Comparison
Compare WMPN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WMPN
- ANL
- Stock Information
- Founded
- WMPN 1870
- ANL 2004
- Country
- WMPN United States
- ANL Cayman Islands
- Employees
- WMPN N/A
- ANL N/A
- Industry
- WMPN Savings Institutions
- ANL
- Sector
- WMPN Finance
- ANL
- Exchange
- WMPN Nasdaq
- ANL Nasdaq
- Market Cap
- WMPN 112.6M
- ANL 115.1M
- IPO Year
- WMPN N/A
- ANL 2023
- Fundamental
- Price
- WMPN $13.02
- ANL $2.77
- Analyst Decision
- WMPN Buy
- ANL Strong Buy
- Analyst Count
- WMPN 1
- ANL 2
- Target Price
- WMPN $14.00
- ANL $9.00
- AVG Volume (30 Days)
- WMPN 89.0K
- ANL 29.8K
- Earning Date
- WMPN 10-16-2024
- ANL 08-08-2024
- Dividend Yield
- WMPN 0.92%
- ANL N/A
- EPS Growth
- WMPN N/A
- ANL N/A
- EPS
- WMPN N/A
- ANL N/A
- Revenue
- WMPN $20,360,000.00
- ANL $5,000,000.00
- Revenue This Year
- WMPN N/A
- ANL N/A
- Revenue Next Year
- WMPN N/A
- ANL N/A
- P/E Ratio
- WMPN N/A
- ANL N/A
- Revenue Growth
- WMPN N/A
- ANL N/A
- 52 Week Low
- WMPN $10.80
- ANL $1.85
- 52 Week High
- WMPN $13.45
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- WMPN 56.24
- ANL 53.97
- Support Level
- WMPN $12.83
- ANL $2.50
- Resistance Level
- WMPN $13.45
- ANL $3.50
- Average True Range (ATR)
- WMPN 0.28
- ANL 0.47
- MACD
- WMPN -0.02
- ANL -0.00
- Stochastic Oscillator
- WMPN 63.57
- ANL 40.48
About WMPN William Penn Bancorporation
William Penn Bancorporation operates as an independent community financial services provider. The bank offers traditional banking and related financial services to individual, business, and government customers. Through its branch and automated teller machine network, the bank offers a full array of commercial and retail financial services, including; the taking of time, savings, and demand deposits; the making of commercial, consumer, and mortgage loans; and the providing of other financial services.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.